Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 7/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22128373 | 0.82 | HTR7 (0.45) | DUTHTR2AHTR2CHTR7 | |
| SCHEMBL2392560 | 0.81 | TNF (0.39) | PSMB1PSMB5TNFMCL1KDM4E | |
| SCHEMBL1710275 | 0.80 | PSMB1 (0.40) | PSMB1PSMB5TNFGRM2MCL1 | |
| SCHEMBL20786907 | 0.80 | HTR7 (0.42) | PSMB1PSMB5TNFGRM2MCL1 | |
| SCHEMBL1710500 | 0.78 | MCL1 (0.35) | PSMB1PSMB5MCL1LMNA | |
| SCHEMBL1500330 | 0.77 | PSMB1 (0.42) | PSMB1PSMB5TNFGRM2MCL1 | |
| SCHEMBL22128294 | 0.76 | HTR6 (0.34) | — | |
| SCHEMBL22128209 | 0.74 | KRAS (0.35) | — | |
| SCHEMBL22128174 | 0.74 | CNR1 (0.30) | — | |
| SCHEMBL22128290 | 0.74 | ALDH1A1 (0.34) | POLBLMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| EP-2344472-A1 | ISOQUINOLINONE DERIVATIVES | AstraZeneca AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010039079-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | DUT 1059/4885PSMB1 3437/4885PSMB5 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.